Luneau Technology and Optovue Announce Merger

France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue.

Terms of the deal were not disclosed. 

Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology to diagnose and manage eye diseases. Dr. Marc Abitbol, CEO of Luneau Technology, will preside over the newly merged company, while Optovue CEO Peter Wyles will join the global leadership team.

“We’re two agile companies with a startup mentality of innovation and flexibility. Together, we now have a full pipeline that covers everything for visual health. Optovue’s OCT expertise, stellar reputation and primary position in the medical eye care market, and complementary portfolio of products, make us an ideal partner, so our combined company can offer complete end-to-end solutions in retail, refraction and medical markets for primary eye care,"  Dr. Abitbol said in a company news release.

The group has combined sales of $176 million, 700 employees in 120 countries.

Luneau Technology USA recently announced that its new Visionix VX650, a technology with multimodal anterior and posterior segment analysis, is now FDA-approved and available for sale in the United States. ECPs can experience the new product firsthand by requesting a live demo at Luneau Technology’s Vision Expo West booth or by scheduling a virtual demo with a sales specialist. Later this year, Optovue will also be launching a new OCT-A screening device.

“One technology will look at the front of the eye, like a camera, and the other the back of the eye so our technologies are very complementary,” Dr. Abitbol said. These new technologies aim to transform and improve access to all patients in the United States and Canada, to help preserve their visual health.